Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
0.9981
-0.1619 (-13.96%)
At close: Apr 1, 2025, 4:00 PM
1.000
+0.002 (0.19%)
After-hours: Apr 1, 2025, 4:34 PM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 3 or -7.50% compared to the previous year.
Employees
37
Change (1Y)
-3
Growth (1Y)
-7.50%
Revenue / Employee
n/a
Profits / Employee
-$652,162
Market Cap
1.46M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APVO News
- 12 days ago - RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment - Accesswire
- 14 days ago - Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy - Accesswire
- 26 days ago - Aptevo to Participate in March Conferences - Accesswire
- 6 weeks ago - Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 6 weeks ago - Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update - Accesswire
- 2 months ago - Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - Accesswire
- 3 months ago - Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - Accesswire
- 3 months ago - 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - Accesswire